BioOutsource Bioanalysis Experts Attending Major Biosimilar Conferences November 16-19

Offering scientists an opportunity for face-to-face meetings to discuss strategies for accelerating biosimilar development

Glasgow, UK – November 12, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced its expert technical staff will be speaking at and/or attending BIOLATAM, Biosimilars LATAM and Biosimilars and Biobetters conferences from November 16-19. This will provide developers of biosimilars with an excellent opportunity to discuss the optimum assay design for rapid and accurate biosimilar characterisation and comparison studies.

At BIOLATAM 2015 in Chile (www.ebdgroup.com/blt/index.php), scientists will be able to hear bioanalysis expert, Dr Verna McErlane, Director of Business Development for Americas, at SSB BioOutsource presenting on Tuesday, November 17 from 3–4pm in the Salón El Canelo. In a session entitled, ‘Integrated solutions and services from research to production in bioprocess’ Dr McErlane will explain the types of bioanalytical testing available and how to select the right assays for characterising biological activity from discovery through the clinical phases of biologics development.

McErlane is presenting alongside, bioprocess specialist, Javier Lobo, Field Marketing Manager Latin America, Application Specialist Spain-Portugal, Fermentation Technologies at SSB Spain. Lobo will detail how bioanalytical testing is integrated with innovative upstream and downstream bioprocess development, making this a must-visit presentation at BIOLATAM for any scientists looking to ensure they have the latest information about the most rapid and cost-effective, strategies for developing their biosimilars.

Researchers that cannot attend the presentation can also connect with Dr McErlane and Javier Lobo, as well as other bioprocess experts on SSB booth #20.

Following BIOLATAM, Dr McErlane, will be attending Biosimilars LATAM 2015 in Brazil (http://pharma.flemingeurope.com/biosimilars-latam-forum) where she would welcome technical meetings and discussions with scientists requiring advice on the types of bioanalysis to utilise when developing biosimilars.

Also available for discussion about the range of assays for biosimilar characterisation and comparability is bioanalysis expert, Dr Catriona Thomson Associate Director of Bioanalytical Technical Services, at SSB BioOutsource. Dr Thomson is attending Biosimilars and Biobetters 2015 in the USA (www.smi-online.co.uk/pharmaceuticals/northamerica/BioSimilars-USA, where she is happy to be contacted for one-one meetings.

Dr Verna McErlane at SSB BioOutsource commented: “Selecting the best analytical tools to use for biosimilar characterisation and comparability can be very daunting. This is being made more complicated as regulators are becoming increasingly demanding in respect to sensitivity and accuracy of assays to prove comparability between innovator and biosimilar drugs.”

McErlane continued: “I’m delighted that Catriona Thomson and I are going to be at these major biosimilar conferences in November as this allows us to meet scientists and explore the issues they have with their testing. We look forward to meeting them and to discussing which bioanalytical strategies they should consider adopting for optimising the timelines and costs of their biosimilar development.”

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge products and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,700 people, and in 2014 earned sales revenue of 683.5 million euros.

 

For further information, please contact: 

Gemma Fulton, Marketing Manager

Sartorius Stedim BioOutsource Ltd, Glasgow, United Kingdom

Phone: +44(0)141.946.4222; Fax +44(0)141.946.4552

 

 

 

 

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.